Drug Trial Radar · NCT04707326
Defining the Potency of DTG/3TC for Suppressed HIV Patients in Real-life: the DUALING Study
Last checked: Nov 19, 2026Latest source record: Dec 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
2,040
Actual
Start
Nov 1, 2019
Primary completion
Nov 1, 2023
Study completion Nov 1, 2026
Sponsor
- Lead sponsor
- Erasmus Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Maasstad Hospital; Haaglanden Medical Centre; Catharina Ziekenhuis Eindhoven; Elisabeth-TweeSteden Ziekenhuis; Rijnstate Hospital; Admiraal de Ruyter Hospital; Spaarne Gasthuis; Medisch Spectrum Twente
- First posted
- Jan 13, 2021
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to determine real-life clinical efficacy of virally suppressed patienst switching to DTG/3TC compared to DTG triple drug cART controls
Conditions
- Hiv
Interventions
Dolutegravir / Lamivudine PillDrug
HIVRNA suppressed patients without documented M184V mutation in HIV RT and who are hepatitis B immune or have no risk factors for acquiring hepatitis B
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy On Treatment (OT)Time frame: 1 year
- Efficacy Intention to Treat (ITT)Time frame: 1 year
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Rijnstate Hospital
Arnhem, Netherlands
Catharina Ziekenhuis
Eindhoven, Netherlands
Medisch Spectrum Twente
Enschede, Netherlands
Admiraal de Ruyter Ziekenhuis
Goes, Netherlands
Spaarne Gasthuis
Haarlem, Netherlands
Erasmus MC
Rotterdam, Netherlands
MC Haaglanden
Rotterdam, Netherlands
Maasstad Hospital
Rotterdam, Netherlands
Elisabeth Tweesteden Hospital
Tilburg, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.